Double Blow For Sangamo’s Zinc Finger Approach As Novartis And Biogen Deals Collapse
Validation Efforts Stalled Again
The US biotech is facing yet another setback on its journey to proof-of-concept for its proprietary gene editing technology as two pharma firms back out of collaborations in the neurological space.
